

# Jordan D Berlin

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1230971/publications.pdf>

Version: 2024-02-01

69  
papers

12,161  
citations

361413

20  
h-index

114465

63  
g-index

73  
all docs

73  
docs citations

73  
times ranked

12702  
citing authors

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 1  | First-in-Human PET Imaging and Estimated Radiation Dosimetry of I-[ <sup>11</sup> C]-Glutamine in Patients with Metastatic Colorectal Cancer. <i>Journal of Nuclear Medicine</i> , 2022, 63, 36-43.  | 5.0 | 13        |
| 2  | Trends in the Incidence and Treatment of Early-Onset Pancreatic Cancer. <i>Cancers</i> , 2022, 14, 283.  | 3.7 | 19        |
| 3  | External Validation of a Clinical Score for Patients With Neuroendocrine Tumors Under Consideration for Peptide Receptor Radionuclide Therapy. <i>JAMA Network Open</i> , 2022, 5, e2144170.   | 5.9 | 5         |
| 4  | Phase 2 study of 9-ING-41, a small molecule selective glycogen synthase kinase-3 beta (GSK-3 $\beta$ ) inhibitor, with gemcitabine/nab-paclitaxel (GnP) in first-line advanced pancreatic ductal adenocarcinoma (PDAC).. <i>Journal of Clinical Oncology</i> , 2022, 40, 578-578.            | 1.6 | 0         |
| 5  | First-in-human trial exploring safety, antitumor activity, and pharmacokinetics of Sym013, a recombinant pan-HER antibody mixture, in advanced epithelial malignancies. <i>Investigational New Drugs</i> , 2022, , 1.  | 2.6 | 5         |
| 6  | A phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of TST001 in patients with locally advanced or metastatic solid tumors.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS375-TPS375.  | 1.6 | 4         |
| 7  | Phase I trial of ATM inhibitor M3541 in combination with palliative radiotherapy in patients with solid tumors. <i>Investigational New Drugs</i> , 2022, 40, 596-605.  | 2.6 | 18        |
| 8  | Adjuvant Therapy for Stage II Colon Cancer: ASCO Guideline Update. <i>Journal of Clinical Oncology</i> , 2022, 40, 892-910.  | 1.6 | 85        |
| 9  | Safety and Efficacy of Avelumab in Small Bowel Adenocarcinoma. <i>Clinical Colorectal Cancer</i> , 2022, 21, 236-243.  | 2.3 | 6         |
| 10 | Phase Ib/II Trial of Ribociclib in Combination with Binimetinib in Patients with <i>NRAS</i> -mutant Melanoma. <i>Clinical Cancer Research</i> , 2022, 28, 3002-3010.  | 7.0 | 18        |
| 11 | Alternative biweekly dosing schedule of trifluridine-tipiracil (TAS-102) reduces rates of myelosuppression while maintaining therapeutic efficacy in patients (pts) with previously treated metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2022, 40, 3559-3559. | 1.6 | 1         |
| 12 | Efficacy and safety profile of antivascular endothelial growth factor receptor tyrosine kinase inhibitors (avRTKIs) in patients (Pts) with neuroendocrine tumors (NETs): A systematic review and meta-analysis (SRMA).. <i>Journal of Clinical Oncology</i> , 2022, 40, e16216-e16216.       | 1.6 | 0         |
| 13 | A clinical score (CS) for patients with well-differentiated neuroendocrine tumors (WD NETs) under consideration for peptide receptor radionuclide therapy (PRRT) with Lu 177-dotatate.. <i>Journal of Clinical Oncology</i> , 2021, 39, 363-363.   | 1.6 | 1         |
| 14 | A clinical score for neuroendocrine tumor patients under consideration for Lu-177-DOTATATE therapy. <i>Endocrine-Related Cancer</i> , 2021, 28, 203-212.   | 3.1 | 4         |
| 15 | Quality of Life in Adult and Pediatric Patients with Tropomyosin Receptor Kinase Fusion Cancer Receiving Larotrectinib. <i>Current Problems in Cancer</i> , 2021, 45, 100734.  | 2.0 | 9         |
| 16 | Validation of a clinical score (CS) for patients (pts) with well-differentiated neuroendocrine tumors (WD NETs) under consideration for peptide receptor radionuclide therapy (PRRT) with Lu 177 dotatate.. <i>Journal of Clinical Oncology</i> , 2021, 39, 4109-4109.                       | 1.6 | 0         |
| 17 | Long-term efficacy and safety of larotrectinib in an integrated dataset of patients with TRK fusion cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, 3108-3108.  | 1.6 | 19        |
| 18 | Pancytopenia in a Patient With Metastatic Well-Differentiated Neuroendocrine Tumor After Peptide Receptor Radionuclide Therapy. <i>JAMA Oncology</i> , 2021, 7, 1060.  | 7.1 | 1         |

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 19 | Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513. <i>Clinical Cancer Research</i> , 2021, 27, 6314-6322.                            | 7.0  | 22        |
| 20 | Racial disparity in taxane-induced neutropenia among cancer patients. <i>Cancer Medicine</i> , 2021, 10, 6767-6776.  | 2.8  | 4         |
| 21 | Systemic Therapy Improvements Will Render Locoregional Treatments Obsolete for Patients with Cancer with Liver Metastases. <i>Surgical Oncology Clinics of North America</i> , 2021, 30, 189-204.  | 1.5  | 0         |
| 22 | A phase Ib study of NUC-3373 in combination with standard therapies in advanced/metastatic colorectal cancer (NuTide:302).. <i>Journal of Clinical Oncology</i> , 2021, 39, 93-93.   | 1.6  | 2         |
| 23 | Comparison of Design, Eligibility, and Outcomes of Neuroendocrine Neoplasm Trials Initiated From 2000 to 2009 vs 2010 to 2020. <i>JAMA Network Open</i> , 2021, 4, e2131744.   | 5.9  | 4         |
| 24 | Safety and Efficacy of Andeciximab (GS-5745) Plus Gemcitabine and Nab-Paclitaxel in Patients with Advanced Pancreatic Adenocarcinoma: Results from a Phase I Study. <i>Oncologist</i> , 2020, 25, 954-962.   | 3.7  | 14        |
| 25 | Combined blockade of EGFR and glutamine metabolism in preclinical models of colorectal cancer. <i>Translational Oncology</i> , 2020, 13, 100828.   | 3.7  | 25        |
| 26 | Immunotherapy After Immunotherapy: Response Rescue in a Patient With Microsatellite Instability-high Colorectal Cancer Post-Pembrolizumab. <i>Clinical Colorectal Cancer</i> , 2020, 19, 137-140.  | 2.3  | 20        |
| 27 | Immune-Related Adverse Events and Immune Checkpoint Inhibitor Efficacy in Patients with Gastrointestinal Cancer with Food and Drug Administration-Approved Indications for Immunotherapy. <i>Oncologist</i> , 2020, 25, 669-679.                             | 3.7  | 30        |
| 28 | Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. <i>Lancet Oncology</i> , The, 2020, 21, 531-540.   | 10.7 | 608       |
| 29 | Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate: an analysis of the NETTER-1 study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2372-2382. | 6.4  | 79        |
| 30 | Phase I Study of Trifluridine/Tipiracil Plus Irinotecan and Bevacizumab in Advanced Gastrointestinal Tumors. <i>Clinical Cancer Research</i> , 2020, 26, 1555-1562.  | 7.0  | 10        |
| 31 | Recent advances in the treatment of pancreatic cancer. <i>F1000Research</i> , 2020, 9, 131.  | 1.6  | 52        |
| 32 | Evaluation of determinants for age disparities in the survival improvement of colon cancer: results from a cohort of more than 486,000 patients in the United States. <i>American Journal of Cancer Research</i> , 2020, 10, 3395-3405.                      | 1.4  | 1         |
| 33 | Adenocarcinoma Ex-Goblet Cell: a Retrospective Experience. <i>Journal of Gastrointestinal Cancer</i> , 2019, 50, 709-715.  | 1.3  | 2         |
| 34 | Perioperative Gemcitabine+ Erlotinib Plus Pancreaticoduodenectomy for Resectable Pancreatic Adenocarcinoma: ACOSOG Z5041 (Alliance) Phase II Trial. <i>Annals of Surgical Oncology</i> , 2019, 26, 4489-4497.  | 1.5  | 19        |
| 35 | First-in-Human Phase I Study of Aprutumab Ixadotin, a Fibroblast Growth Factor Receptor 2 Antibody-Drug Conjugate (BAY 1187982) in Patients with Advanced Cancer. <i>Targeted Oncology</i> , 2019, 14, 591-601.  | 3.6  | 43        |
| 36 | PD-L1 Expression Patterns in Microsatellite Instability-High Intestinal Adenocarcinoma Subtypes. <i>American Journal of Clinical Pathology</i> , 2019, 152, 384-391.   | 0.7  | 5         |

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 37 | Duration of Oxaliplatin-Containing Adjuvant Therapy for Stage III Colon Cancer: ASCO Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2019, 37, 1436-1447.   | 1.6  | 53        |
| 38 | Phase I study combining the aurora kinase a inhibitor alisertib with mFOLFOX in gastrointestinal cancer. <i>Investigational New Drugs</i> , 2019, 37, 315-322.   | 2.6  | 11        |
| 39 | A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2019, 120, 183-189.                       | 6.4  | 38        |
| 40 | Impact of Peritoneal Metastasis on Survival of Patients With Small Intestinal Neuroendocrine Tumor. <i>American Journal of Surgical Pathology</i> , 2019, 43, 559-563.   | 3.7  | 10        |
| 41 | Peritoneal Carcinomatosis in Well-Differentiated Small-Intestinal Neuroendocrine Tumors with Mesenteric Tumor Deposits. <i>Journal of Medical &amp; Surgical Pathology</i> , 2019, 4, 1-10.                            | 0.2  | 1         |
| 42 | First-in-human phase I dose escalation study of MK-8033 in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2018, 36, 860-868.  | 2.6  | 4         |
| 43 | Pharmacological blockade of ASCT2-dependent glutamine transport leads to antitumor efficacy in preclinical models. <i>Nature Medicine</i> , 2018, 24, 194-202.   | 30.7 | 303       |
| 44 | Andecaliximab/GS-5745 Alone and Combined with mFOLFOX6 in Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Results from a Phase I Study. <i>Clinical Cancer Research</i> , 2018, 24, 3829-3837.          | 7.0  | 69        |
| 45 | Current Concepts in the Treatment of Resectable Pancreatic Cancer. <i>Current Oncology Reports</i> , 2018, 20, 39.   | 4.0  | 17        |
| 46 | A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumours. <i>British Journal of Cancer</i> , 2018, 118, 938-946.  | 6.4  | 29        |
| 47 | Frequent <i>BRAF</i> mutations suggest a novel oncogenic driver in colonic neuroendocrine carcinoma. <i>Journal of Surgical Oncology</i> , 2018, 117, 284-289.   | 1.7  | 21        |
| 48 | Dual Src and EGFR inhibition in combination with gemcitabine in advanced pancreatic cancer: phase I results. <i>Investigational New Drugs</i> , 2018, 36, 442-450.   | 2.6  | 16        |
| 49 | The eye of the beholder: orbital metastases from midgut neuroendocrine tumors, a two institution experience. <i>Cancer Imaging</i> , 2018, 18, 47.   | 2.8  | 24        |
| 50 | Harnessing the Immune System in Pancreatic Cancer. <i>Current Treatment Options in Oncology</i> , 2018, 19, 48.  | 3.0  | 17        |
| 51 | A multicenter study of the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib plus durvalumab in patients with relapsed/refractory (R/R) solid tumors.. <i>Journal of Clinical Oncology</i> , 2018, 36, 2578-2578.     | 1.6  | 19        |
| 52 | Hidden Figures: Occult Intra-Cardiac Metastases in Asymptomatic Neuroendocrine Tumor Patients. <i>Journal of Oncology and Cancer Research</i> , 2018, 2, 23-27.  | 0.1  | 4         |
| 53 | In liver metastases from small intestinal neuroendocrine tumors, SSTR2A expression is heterogeneous. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 470, 545-552. | 2.8  | 14        |
| 54 | Academic Cancer Center Phase I Program Development. <i>Oncologist</i> , 2017, 22, 369-374.   | 3.7  | 0         |

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 55 | Phase II study of the Multikinase inhibitor of angiogenesis, Linifanib, in patients with metastatic and refractory colorectal cancer expressing mutated KRAS. <i>Investigational New Drugs</i> , 2017, 35, 491-498.              | 2.6  | 7         |
| 56 | Expression of PD-1 and PD-L1 in poorly differentiated neuroendocrine carcinomas of the digestive system: a potential target for anti-PD-1/PD-L1 therapy. <i>Human Pathology</i> , 2017, 70, 49-54.                               | 2.0  | 38        |
| 57 | A phase I trial investigating pulsatile erlotinib in combination with gemcitabine and oxaliplatin in advanced biliary tract cancers. <i>Investigational New Drugs</i> , 2017, 35, 95-104.  | 2.6  | 6         |
| 58 | Epacadostat plus nivolumab in patients with advanced solid tumors: Preliminary phase I/II results of ECHO-204. <i>Journal of Clinical Oncology</i> , 2017, 35, 3003-3003.  | 1.6  | 69        |
| 59 | Phase I trial of vorinostat added to chemoradiation with capecitabine in pancreatic cancer. <i>Radiotherapy and Oncology</i> , 2016, 119, 312-318.   | 0.6  | 51        |
| 60 | Phase II Study of Olaparib (AZD5363) After Standard Systemic Therapies for Disseminated Colorectal Cancer. <i>Oncologist</i> , 2016, 21, 172-177.  | 3.7  | 58        |
| 61 | Targeting metastatic colorectal cancer – present and emerging treatment options. <i>Pharmacogenomics and Personalized Medicine</i> , 2014, 7, 137.   | 0.7  | 14        |
| 62 | Enabling a Genetically Informed Approach to Cancer Medicine: A Retrospective Evaluation of the Impact of Comprehensive Tumor Profiling Using a Targeted Next-Generation Sequencing Panel. <i>Oncologist</i> , 2014, 19, 616-622. | 3.7  | 94        |
| 63 | Phase II Trial of T138067, a Novel Microtubule Inhibitor, in Patients with Metastatic, Refractory Colorectal Carcinoma. <i>Clinical Colorectal Cancer</i> , 2008, 7, 44-47.  | 2.3  | 13        |
| 64 | Ethics in Oncology: Consulting for the Investment Industry. <i>Journal of Clinical Oncology</i> , 2007, 25, 444-446.   | 1.6  | 10        |
| 65 | Panitumumab with Irinotecan/Leucovorin/5-Fluorouracil for First-Line Treatment of Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2007, 6, 427-432.  | 2.3  | 95        |
| 66 | Uncommon Cancers of the Stomach. , 2006, , 352-366.  |      | 1         |
| 67 | Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer. <i>New England Journal of Medicine</i> , 2004, 350, 2335-2342.   | 27.0 | 9,850     |
| 68 | Current and future strategies for treating metastatic pancreatic cancer. <i>Clinical Advances in Hematology and Oncology</i> , 2004, 2, 510-2.   | 0.3  | 0         |
| 69 | Warfarin-5-FU Interaction – A Consecutive Case Series. <i>Pharmacotherapy</i> , 1999, 19, 1445-1449.   | 2.6  | 54        |